Maker of a hair gummy plans a small trial in women with thinning hair

Xtressé, a company that already sells a hair-growth gummy through doctors’ offices, has registered a study to test it in women who feel their hair is getting thinner.¹ The record appeared on ClinicalTrials.gov, the US government’s public registry of clinical studies, on November 5, 2026.¹ The study is not yet recruiting, no one has taken part, and no results exist yet.¹ The sponsor is Restore Biologics Holdings, Inc., which does business as Xtressé.¹

This is the first Biohack article on the gummy. It covers a plan, not a finding.

What the planned study will do

The registry describes a randomized, double-blind, placebo-controlled study.¹ In plain terms, 30 women will be split by chance into two groups: one takes the Xtressé gummy, the other takes a placebo (a dummy gummy).¹ Neither the women nor the study staff will know who is getting which.¹ This kind of design is meant to keep hopes and expectations from tilting the results.

The enrollment target of 30 is listed as an estimate.¹ The study runs for six months.¹ Women who qualify will make three in-person visits, receiving a 90-day supply of gummies at the first and second visits to cover the full period.¹ At each visit, staff will take photographs and analyze the scalp to look at changes in hair volume, thickness and growth.¹

The main measure is hair density, meaning how many hairs grow in a patch of scalp, from enrollment to the end of treatment at six months.¹ It will be read with a tool called Canfield HairMetrix, a photo-based method known as phototrichogram analysis that counts hairs in close-up scalp images.¹ According to the registry summary, the aims are to check changes in thick, fully grown hairs (called terminal hairs), changes in total hair density and the width of each hair, and how satisfied the women are with their hair and with taking the product.¹

The registry lists the condition as androgenetic alopecia, the common pattern hair loss linked to hormones and genes, while the study title describes the women as having “self-perceived” thinning hair, meaning they themselves notice it.¹ The record does not label the study with a drug-style phase, because the product is sold as a supplement rather than a drug.¹ The planned start date is November 16, 2026, and the main data collection is expected to finish in August 2027.¹

What it does not show yet

A registry entry is a statement of intent. It does not say whether the gummy changes hair in women, and it cannot. Results have not been posted.¹

Even once results arrive, the study will have limits that are visible from its plan:

• Size. With about 30 women split into two groups, the study is small.¹ Small studies can miss real effects or overstate chance ones.
• Length. Six months of treatment says little about what happens over years or after stopping.¹
• Who is enrolled. The women are described by their own sense that their hair is thinning, so the results may not apply to every cause of hair loss.¹
• Who runs it. The company that makes and sells the gummy is the sponsor.¹ Company-funded studies can be well designed, but independent checks carry extra weight.

Who is behind the gummy

Xtressé announced its launch on February 10, 2025, in a press release from Orlando, Florida.² The release named two co-founders, Michael Mazen Jafar and Dr. Matt Leavitt, a dermatologist who said he had performed more than 70,000 hair procedures.² A later trade report named another co-founder, Trillitye Paullin, PhD.³

The gummy was the company’s first product.² The company describes it as sugar-free and biotin-free.² Biotin is a B vitamin common in hair supplements; Leavitt said in the launch release that it “lacks proven efficacy.”² The company says the gummy contains blends it calls X3 Technologies, with ingredients including NAD+ (a molecule involved in how cells make energy), pumpkin seed extract, taurine and saw palmetto, plus vitamins A, B3, B6, C, D3 and E and zinc.²

The research the company pointed to for its ingredients is mixed in kind. Its launch release footnoted, for example, a study of pumpkin oil on hair growth in mice and a 16-week placebo-controlled study of a saw palmetto oil in people with pattern hair loss.² Those are studies of single ingredients, not of the gummy itself.² The release also carried the standard notice that its statements had not been evaluated by the US Food and Drug Administration and that the gummy is not intended to diagnose, treat, cure or prevent any disease.²

The gummy was launched to be sold only through professional offices.² By February 2026, the company said about 100,000 consumers were using it and more than 1,000 medical and professional practices carried it, according to Nutraceuticals World, a supplement-industry publication.³ Some skin-care retailers also promote it; one retailer’s blog, which sells the product, called it dermatologist-developed and said it nourishes hair follicles, without citing a trial of the gummy.⁴

What the company has said about results so far

The company has already made claims about results. Nutraceuticals World reported in February 2026 that, in an “ongoing, IRB-approved study,” 90% of patients with androgenetic alopecia had shown measurable reductions in hair loss, attributing the figure to the company.³ An IRB is an ethics board that reviews research involving people. The report did not give the number of patients, whether there was a comparison group, or how hair loss was measured.³ The sources available to Biohack include no published data from that study, and they do not say whether it is connected to the newly registered trial.

The same report covered a wider product line that includes a scalp serum and a concentrate applied in doctors’ offices.³ Paullin said the serum produced a 165% increase in growth of a type of human hair-root cell compared with untreated cells.³ That result was in cells in a lab dish, not in people, and it concerns the serum, not the gummy.³

The new registry entry is different from these statements in one important way: it lays out in public, before the study starts, what will be measured and how, including a comparison with a dummy gummy.¹

How it fits the field

Hair thinning is common. Xtressé’s launch release cited a National Library of Medicine figure of more than 80 million Americans affected by pattern hair loss.² The retailer blog cited the American Hair Loss Association as saying roughly half of women have some hair loss by age 50.⁴

Supplements for hair are widely sold, and many are marketed without tests of the finished product against a placebo. Registering a blinded, placebo-controlled study is a step toward that kind of test. Whether it settles anything will depend on whether it is completed, how many women finish, and whether the full results, including any side effects, are reported.

What to watch next

• Recruitment. Whether the study starts on its listed date of November 16, 2026, and reaches its target of about 30 women.¹
• Changes to the plan. Any edits to the registry’s main measure, size or timeline before results come out.
• Results. Main data collection is expected to finish in August 2027.¹ Watch for results posted on the registry or published in a peer-reviewed journal, rather than only in company announcements.
• The earlier study. Whether the company publishes full data from the ongoing study behind its 90% claim.³

Until then, the gummy’s effect on hair in women has not been shown in a completed, published trial of the product.